Veterinary respiratory diseases are the most common disease that affects livestock and small animals. Veterinary respiratory diseases are the second leading cause of mortality in various animals. Veterinary respiratory disease caused to the animals varies from animal to animal, and it depends on upon the causative agent.
Veterinary respiratory disease resulting from different types of bacteria (bacteria, viruses, weak immune system, temperature fluctuations and improper ventilation are the few factors responsible for causing veterinary respiratory diseases.
Due to veterinary respiratory diseases, it is leading to high mortality rates of animals and causing economic losses. For instance, the bovine respiratory disease is most common in cattle and swine respiratory disease in pigs. Bovine respiratory disease mostly caused by the bacterial agents Pasteurella multocida, Histophilus somni, Mycoplasma bovis, and Mannheimia haemolytica. Various medicines are available in the market to treat Veterinary respiratory diseases.
Most commonly used drugs to treat veterinary respiratory diseases are antimicrobial agents, Non-steroidal anti-inflammatory drugs (NSAID’s), Bronchodilators, Mucolytic agents, Oral rehydration fluids, and immunomodulators. However, treatments are becoming ineffective owing to increase in bacterial, viral resistance in the animals and lack of proper diagnosis are significant factors resulting increase in veterinary respiratory diseases. Hence newer drugs are coming into the market to treat veterinary respiratory disease conditions.
In 2011, Merial (Boehringer Ingelheim), launched Zactran (Gamithromycin) to treat and control bovine respiratory disease conditions. In 2008, Zoetis (Pfizer), got EU approval for Draxxin® (tulathromycin) to treat Haemophilus parasuis (Glässer’s disease) in pigs, the uniqueness of the drug is it acts for ten days this intends to reduce the frequent dosage to the animals.
In 2015, Ceva group launched respiratory vaccine to prevent from Mycoplasma hyopneumoniae infections. To decrease the antibacterial resistant animals researchers are exploring new therapeutic approaches like bacteriophage therapy and bacterial peptides to treat veterinary respiratory disease conditions.
Request a Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-2526
Veterinary Respiratory Disease Market: Drivers and Restraints
The global market for veterinary respiratory disease market is driven due to increase in respiratory infections, lack of drugs to treat specific pathogens, to decrease the mortality rates of animals are driving the growth of veterinary respiratory disease market during the forecast period. In 2011, U.S Department of Agriculture’s National Animal Health Monitoring System (NAHMS) had conducted study to understand the treatment cost and incidence of respiratory diseases in cattle.
The results showed that around 16.2 percent of cattle affected with respiratory diseases and treatment cost for cattle is the $23.60/per case. The cost for treating veterinary respiratory disease has increased significantly over the years. In the UK, cattle industry spends around 60 million euros annually to treat respiratory disease conditions.
Veterinary respiratory disease is more commonly affected by the young calves and animals this due to improper development of immune system. The major restraints of the market are the cost of the drugs, government regulations to reduce the usage of antibiotics are hindering the growth of this market.
Veterinary Respiratory Disease Market: Overview
Cost effective, long-acting drugs would create attractive growth opportunities for the veterinary respiratory disease market over the forecast period. To treat respiratory diseases in cattle critically important, antibiotics like aminoglycosides, cephalosporins and penicillins are most commonly used followed by macrolides and fluoroquinolones.
In the case of respiratory diseases in pigs, 47% of tetracyclines are used followed by pencillins (21%), macrolides (10%) and potentiated sulphonamides (8%). Rifampicin is commonly used to treat respiratory infections in horses. In the veterinary respiratory disease market antibiotics and vaccines occupies the significant share in the market and dominates during the forecast period.
Based on distribution channel, veterinary pharmacies dominated the current market and expected to dominate during the forecast period. The number of e-commerce pharmacies is increasing due to increasing penetration of internet across the globe. Both parenteral and oral routes are most commonly used to treat the veterinary respiratory diseases.
Veterinary Respiratory Disease Market: Regional Overview
Region-wise, the global veterinary respiratory disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America dominated the global market for veterinary respiratory disease owing to established health care and practiced veterinary practitioners are driving the growth of this market. Asia-Pacific is expected to surpass the European market during the forecast owing to increase in the cattle population.
Ask for Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb-2526
Veterinary Respiratory Disease Market: Players
Some of the players in global veterinary respiratory disease market include Zoetis, Merck & Co., Inc., Eli Lilly Company, Virbac group, Bayer, Vetoquinol, Boehringer Ingelheim, Ceva and Bimeda animal health.
The report covers exhaustive analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Nordiccountries, BENELUX)
- Eastern Europe (Russia, Poland, Rest of Eastern Europe)
- Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle Eastand Africa (GCC, S. Africa, N. Africa, Rest Of MEA)
The report is a compilation of first-hand information, qualitative, and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Get In Touch With Our Team For 20% Flat Discount:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-2526
Veterinary Respiratory Disease Market: Segmentation
Veterinary respiratory disease market is segmented on the basis of drug classification, distribution channel, and end user.
Based on the drug classification, the veterinary respiratory disease market is segmented into the following:
- Antibiotics
- Penicillins
- Aminoglycosides
- Cephalosporins
- Others
- Antiparasitics
- NSAID’s
- Antiviral
- Vaccines
Based on the route of administration, the veterinary respiratory disease market is segmented into the following:
- Oral
- Parenteral
- Other
Based on the distribution channel, the veterinary respiratory disease market is segmented into the following:
- Veterinary Pharmacies
- Retail Pharmacies
- E-commerce
Read Related Reports:
Immunoassay Market Size : The global immunoassay market is expected to be worth USD 45.78 billion by 2032, growing at a CAGR of 5% from its current value of USD 29.51 billion in 2022.
3D Printed Medical Implants Market Share : The global demand for 3D printed medical implants is expected to rise at a healthy CAGR of 12.5% to be valued at US$ 2,494.5 million by 2032.
Humanized Mouse Model Market Trends : The global humanized mouse model market is expected to be valued at US$ 92.5 Million in 2022. Throughout the decade spanning 2022-2032
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!
Contact Us:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Enquiries: sales@futuremarketinsights.com